Special populations — assess the product and clinical context
Source-checked guidance · 21 October 2026
Evidence from one indication or trial population cannot automatically be extended to dialysis, decompensated cirrhosis, pregnancy, children or frailty. Review the exact UK product information and relevant specialist pathway. Pharmacokinetic compatibility does not establish clinical benefit or safety in a group excluded from outcome trials.
Source check: 21 October 2026. This chapter summarises selected cautions and source differences; it is not a validated prescribing protocol. Wegovy UK SmPC · Mounjaro UK SmPC
Risk–benefit review and shared decisions
Source-checked guidance · 21 October 2026
- Confirm the authorised indication, formulation and treatment goal.
- Check evidence in the actual patient population and distinguish trial evidence from label wording.
- Assess hydration, nutritional status, concurrent insulin/sulfonylureas, interacting medicines and capacity for follow-up.
- Agree individual goals, safety-netting and the responsible clinical team.
- Reassess if acute illness, surgery, pregnancy or nutritional deterioration changes the balance.
Special-population reference
Source-checked guidance · 21 October 2026
| Scenario | Key assessment | Source / next step |
|---|---|---|
| Heart failure | Phenotype, stability, obesity and existing HF therapy. | Preserved-EF obesity evidence must not be extrapolated to all HFrEF. ESC 2026 |
| Advanced CKD / dialysis | Product-specific renal wording, dehydration and nutritional risk. | Wegovy is not recommended in ESRD; tirzepatide wording differs. Renal section |
| Advanced liver disease | Distinguish non-cirrhotic MASH from cirrhosis and decompensation. | Current authorisation and safety assessment are product-specific. Hepatic section |
| Stroke / TIA | Neurological stability, swallowing, nutrition and the actual indication. | No universal post-stroke waiting period is established here. Stroke section |
| Previous pancreatitis | Cause, recurrence risk and current warning. | Use caution; do not restart the implicated medicine after confirmed pancreatitis. MHRA January 2026 |
| Gallbladder disease | Symptoms and acute biliary disease. | Use the clinical pathway; no routine UDCA prophylaxis is specified here. Biliary section |
| Severe GI disease / gastroparesis | Delayed emptying, vomiting, nutrition and aspiration risk. | Wegovy is not recommended in severe gastroparesis; tirzepatide advises caution. Wegovy · Mounjaro |
| MTC / MEN2 | Jurisdiction and exact product label. | US boxed-warning restrictions must not be imported as a universal UK contraindication. UK Mounjaro SmPC |
| Frailty / sarcopenia | Nutrition, function, treatment burden and goals. | Individualise; avoid a site-invented frailty score cutoff. NICE frailty pathway |
| Older adults / polypharmacy | Interactions, hydration, renal function, insulin and sulfonylureas. | Use product-specific precautions and medicine review. Mounjaro SmPC |
| Surgery / deep sedation | Full anaesthetic risk assessment and mitigation. | UK 2025 consensus supports continuation with individual assessment; follow the anaesthetic team plan. Multidisciplinary consensus |
| Pregnancy / breastfeeding | Product-specific advice and planned-pregnancy washout. | See the reproductive-safety summary below. MHRA advice · Current Mounjaro SmPC |
| Children / adolescents | Age, indication, dose and specialist pathway. | UK Mounjaro: T2DM from age 10, weight management adults. Wegovy: weight management from age 12 with specified criteria. Mounjaro · Wegovy |
| Eating disorders | Current nutritional and mental-health assessment. | Specialist advice; appetite suppression may be inappropriate with active restrictive eating. NICE obesity management |
| Active cancer treatment | Nutrition, cachexia, symptoms and treatment goals. | Oncology/diabetes assessment; no universal rule to stop during all cancer therapy is established here. Person-centred NICE guidance |
| After bariatric surgery | Nutritional intake, hypoglycaemia and procedure-specific factors. | Review in the bariatric/diabetes pathway and check the relevant SmPC. Wegovy SmPC |
Pregnancy, contraception and breastfeeding
Do not use semaglutide or tirzepatide during pregnancy. Before planned conception, stop semaglutide: at least 2 months; tirzepatide: at least 1 month. Liraglutide should be stopped before trying to conceive. Other products require their own advice. MHRA washout table
With tirzepatide, switch to non-oral contraception or add a barrier method for 4 weeks after initiation and each dose increase. Mounjaro SmPC, sections 4.5–4.6
Breastfeeding advice is product-specific and has changed. Wegovy should not be used during breastfeeding. The September 2026 Mounjaro SmPC says tirzepatide could be considered during breastfeeding after new milk-transfer data; maternal food intake and milk nutritional content remain uncertain. The older MHRA public advice (February 2026) still advises avoiding these medicines while breastfeeding. Discuss this dated difference with the treating specialist and use the current product information; this is not a blanket recommendation to start treatment. Wegovy section 4.6 · Mounjaro section 4.6 · MHRA public advice
Heart failure — separate preserved and reduced EF
Source-checked guidance · 21 October 2026
The 2026 ESC heart-failure guidance includes semaglutide and tirzepatide evidence for patients with preserved LVEF and obesity. Benefits demonstrated in this population should not be described as established for every heart-failure phenotype. ESC 2026 guideline
In acute decompensation or advanced symptomatic disease, treatment decisions require the heart-failure team, attention to blood pressure, hydration and nutritional status, and review of established HF therapy. GLP-1-based treatment does not replace that therapy. ESC summary · Wegovy special warnings
Advanced CKD and dialysis — no class-wide renal cutoff
Source-checked guidance · 21 October 2026
Use the actual brand and formulation SmPC. A single eGFR <45 contraindication for all exenatide/lixisenatide formulations is incorrect. MHRA notes that exenatide is no longer marketed in the UK and lixisenatide is no longer authorised. MHRA current UK product context
Current UK Wegovy information requires no dose adjustment for mild, moderate or severe renal impairment, but experience in severe impairment is limited and it is not recommended in end-stage renal disease. Tirzepatide requires no renal dose adjustment, including ESRD, but severe impairment/ESRD experience is limited and caution is needed. This label distinction is not proof of equal outcome evidence in dialysis. Wegovy section 4.2 · Mounjaro section 4.2
Vomiting and diarrhoea can cause dehydration and worsen renal function. Advanced CKD/dialysis decisions should include the renal team and an individual fluid and nutritional assessment; fixed fluid targets and invented monitoring intervals are inappropriate. Mounjaro warnings · Wegovy warnings
KDIGO 2022 remains the published diabetes guideline; the 2026 update is a draft under revision. FLOW data must not be relabelled as invented final “KDIGO 2024” 1A/2B recommendations. KDIGO status
MASH, cirrhosis and hepatic impairment
Source-checked guidance · 21 October 2026
The September 2026 UK Wegovy SmPC includes treatment of adult non-cirrhotic MASH with F2–F3 fibrosis, with diet and exercise. This is distinct from using an obesity or T2DM medicine for a different indication and from treating decompensated cirrhosis. Wegovy indications
Current UK Wegovy and Mounjaro information requires no hepatic dose adjustment. Severe impairment experience is limited and caution is advised. Pharmacokinetic findings should not be presented as evidence that treatment is safe for every patient with decompensated liver disease. Wegovy hepatic-impairment wording · Mounjaro hepatic-impairment wording
Cirrhosis, decompensation, malnutrition, sarcopenia or poor oral intake need hepatology/diabetes assessment and an individual management plan. The UK tirzepatide label does not establish a MASH indication merely because SYNERGY-NASH reported encouraging trial results. Mounjaro indications · Liver trial evidence
Stroke and TIA — assess stability and the prevention indication
Source-checked guidance · 21 October 2026
For long-term semaglutide cardiovascular prevention, NICE TA1152 includes previous ischaemic or haemorrhagic stroke within its established-CVD criteria. This must be distinguished from initiating treatment during an acute stroke. TA1152
Acute timing depends on neurological stability, swallowing and nutrition, glycaemia, concurrent treatment and the responsible stroke team. This reference does not impose an unsupported fixed 2–4-week or 6-month waiting period. A favourable chronic prevention study does not establish treatment of acute stroke.
Pancreatitis history — caution and clear safety-netting
Source-checked guidance · 21 October 2026
MHRA strengthened UK warnings on 29 January 2026, including rare severe, necrotising and fatal reports. A history of pancreatitis requires caution and individual risk–benefit assessment, not a universal UK class contraindication. MHRA safety communication
Severe persistent abdominal pain, possibly radiating to the back and accompanied by nausea/vomiting, requires urgent assessment. Stop the medicine immediately if pancreatitis is suspected; it should not be restarted if pancreatitis is confirmed. Investigate and manage under the relevant clinical pathway. MHRA professional advice
Gallbladder disease — assess symptoms and biliary risk
Source-checked guidance · 21 October 2026
Gallstones and cholecystitis are reported with GLP-1-based treatment and can accompany substantial weight loss. Assess persistent upper abdominal pain, fever or jaundice promptly rather than assuming ordinary treatment-related nausea. Wegovy adverse effects · Mounjaro adverse effects
Use the established biliary-disease pathway to investigate and manage suspected acute disease. Neither automatic ursodeoxycholic-acid prophylaxis nor annual ultrasound is established as a routine GLP-1 prescribing requirement here. Cholecystectomy does not remove every possibility of biliary complications or pancreatitis. NICE gallstone-disease guidance
Visual reference for special clinical scenarios
Each illustration below is paired with a clinical summary and detailed explanation. Click any image to expand. Figures are numbered in teaching order and grouped by theme.
Renal disease
Renal anatomy & GLP-1 prescribing
Image description
The illustration presents Kidney structure relevant to FLOW and CKD dosing.
Clinical interpretation
Semaglutide and liraglutide usable down to eGFR thresholds per SPC; no renal dose adjustment for most weekly agents until dialysis — still individualise volume status.
Nephron — GLP-1 receptor expression
Image description
The illustration presents Proximal tubule GLP-1R may mediate natriuresis and renoprotection.
Clinical interpretation
Experimental and clinical data suggest direct renal effects beyond glycaemia — albuminuria reduction observed in several trials.
Diabetic kidney disease pathology
Image description
The illustration presents Glomerulosclerosis and albuminuria as treatment targets.
Clinical interpretation
FLOW trial supports GLP-1 RA in albuminuric CKD with T2DM — often combined with SGLT2 inhibitor and RAAS blockade.
Renal physiology — FLOW trial context
Image description
The illustration presents Haemodynamic and structural renal endpoints in trials.
Clinical interpretation
Composite endpoints include sustained eGFR decline, ESKD, and renal death — clinically meaningful for nephrology referral timing.
Podocyte and glomerular filtration barrier
Image description
The illustration presents Cellular level of albuminuria reduction mechanisms.
Clinical interpretation
Preclinical work suggests GLP-1 RAs reduce inflammation and improve podocyte health — human histological confirmation is limited.
Cardiorenal syndrome
Cardiorenal metabolic syndrome
Image description
The illustration presents Intersection of HF, CKD, and diabetes — combination therapy zone.
Clinical interpretation
Patients with T2DM, HF, and CKD benefit from SGLT2i + GLP-1 RA when tolerated — careful diuretic and BP management required.
Neurohormonal activation in HF/CKD
Image description
The illustration presents RAAS, SNS, and GLP-1 modulatory effects.
Clinical interpretation
GLP-1 RAs do not replace RAAS inhibitors but may add complementary benefits in cardiorenal metabolic syndrome.
Hepatic disease
Hepatic lipogenesis & MASH
Image description
The illustration presents GLP-1 RAs reduce steatosis in MASH trials.
Clinical interpretation
Semaglutide 2.4 mg achieved histological MASH resolution in Phase 3 — regulatory obesity/Mash indications evolving; monitor gallbladder risk.
Hepatic lobule — semaglutide MASH effects
Image description
The illustration presents Liver histology improvements in ESSENCE programme.
Clinical interpretation
Weight loss and direct hepatic effects reduce steatosis and inflammation markers; cirrhosis populations need specialist input.
Hepatocyte metabolism
Image description
The illustration presents Intracellular fat handling under GLP-1R activation.
Clinical interpretation
Reduced de novo lipogenesis and improved insulin sensitivity in liver — complementary to weight loss.
Emerging hepatic therapies landscape
Image description
The illustration presents GLP-1-based combinations in MASH pipeline.
Clinical interpretation
Triple agonists and GLP-1 + FGF21 combinations in development — semaglutide remains current benchmark.
Semaglutide MASH histological outcomes
Image description
The illustration presents NASH resolution and fibrosis improvement data.
Clinical interpretation
Informs hepatology referral and combined lifestyle + pharmacotherapy plans for MASLD.
Neurology
Neuroprotection — Parkinson disease research
Image description
The illustration presents Exploratory GLP-1 RA trials in neurodegeneration.
Clinical interpretation
Exenatide once-weekly showed modest motor benefits in small PD trials; larger studies ongoing — not standard of care.
Hippocampal neurons — cognitive research
Image description
The illustration presents Preclinical neuroprotection hypotheses.
Clinical interpretation
Linked to Alzheimer prevention trials — mechanistic plausibility from reduced neuroinflammation and improved metabolic risk factors.
Neuroendocrine axis
Image description
The illustration presents Hypothalamic–pituitary–peripheral hormone integration.
Clinical interpretation
GLP-1 sits at intersection of metabolic and stress axes — relevant to appetite, mood, and autonomic effects.
Special populations
Female reproductive endocrinology
Image description
The illustration presents PCOS, fertility, and contraception counselling.
Clinical interpretation
GLP-1 RAs improve ovulation and weight in PCOS; discontinue 2 months before planned pregnancy (semaglutide SPC). No adequate human pregnancy data — avoid unless benefit outweighs risk.
Musculoskeletal
Bone microarchitecture & weight loss
Image description
The illustration presents Bone density monitoring with large weight loss.
Clinical interpretation
Weight loss can reduce BMD; FRAX reassessment and resistance exercise advised in older patients on high-dose obesity therapy.
Skeletal muscle & sarcopenia risk
Image description
The illustration presents Lean mass preservation during GLP-1-induced weight loss.
Clinical interpretation
Resistance training and protein targets (1.2–1.6 g/kg/day where appropriate) are recommended especially in older adults and frailty.
Clinical FAQs
Frequently asked questions
Can GLP-1 agonists be used in chronic kidney disease?
Several GLP-1 agonists can be used across a range of renal function and some show renal-protective signals in trials. Dose adjustment and monitoring depend on the specific drug and eGFR; consult the SmPC.